Michael Kaleko Selected Research

SYN-004

1/2019	Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis.
10/2016	Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Kaleko Research Topics

Disease

4	Dysbiosis 05/2019 - 10/2016
3	Whooping Cough (Pertussis) 01/2020 - 12/2015
2	Leukocytosis (Pleocytosis) 01/2020 - 12/2015
2	Infections 01/2019 - 05/2003
2	Sudden Infant Death (SID) 01/2019 - 10/2018
2	Choroidal Neovascularization 12/2004 - 05/2003
2	Retinal Neovascularization 06/2004 - 06/2004
1	Cognitive Dysfunction 01/2020
1	Opportunistic Infections (Opportunistic Infection) 01/2019
1	Clostridium Infections 10/2016
1	Diarrhea 10/2016
1	Vitelliform Macular Dystrophy 12/2004
1	Wounds and Injuries (Trauma) 06/2004
1	Diabetic Retinopathy (Retinopathy, Diabetic) 05/2003
1	Macular Edema 05/2003
1	Neoplasms (Cancer) 05/2003
1	Retinal Detachment (Retinal Detachments) 05/2003
1	Hepatitis 12/2002
1	Vesicular Stomatitis 07/2002
1	Cicatrix (Scar) 02/2002
1	Hemophilia A (Haemophilia) 01/2002

Drug/Important Bio-Agent (IBA)

5	Anti-Bacterial Agents (Antibiotics)IBA 05/2019 - 12/2015
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2004 - 05/2003
3	Retinaldehyde (Retinal)IBA 12/2004 - 05/2003
2	Pertussis ToxinIBA 01/2020 - 12/2015
2	EnzymesIBA 01/2019 - 10/2016
2	SYN-004IBA 01/2019 - 10/2016
2	beta-Lactamases (beta-Lactamase)IBA 01/2019 - 10/2016
2	carbapenemaseIBA 01/2019 - 01/2019
2	Ertapenem (Invanz)FDA Link 01/2019 - 10/2018
1	Alkaline PhosphataseIBA 01/2020
1	Combined Antibody TherapeuticsIBA 01/2020
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2019
1	beta Lactam AntibioticsIBA 01/2019
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2019
1	Amoxicillin (Wymox)FDA LinkGeneric 10/2018
1	AntigensIBA 01/2017
1	OligosaccharidesIBA 01/2017
1	AntibodiesIBA 12/2015
1	Tetracycline (Achromycin)FDA LinkGeneric 12/2004
1	Insulin (Novolin)FDA Link 06/2004
1	Insulin-Like Growth Factor I (IGF-1)IBA 06/2004
1	Doxycycline (Periostat)FDA LinkGeneric 06/2004
1	IntegrinsIBA 05/2003
1	EndostatinsIBA 05/2003
1	Collagen Type XVIII (Type XVIII Collagen)IBA 05/2003
1	ElementsIBA 12/2002
1	Glycoproteins (Glycoprotein)IBA 07/2002
1	Apolipoproteins E (ApoE)IBA 02/2002
1	Peptides (Polypeptides)IBA 02/2002
1	LigandsIBA 02/2002
1	Isoleucine (L-Isoleucine)FDA Link 02/2002
1	Proteins (Proteins, Gene)FDA Link 02/2002
1	Blood Coagulation Factors (Coagulation Factor)IBA 01/2002
1	Factor VIII (Coagulation Factor VIII)IBA 01/2002

Therapy/Procedure

1	Oral Administration 01/2019
1	Therapeutics 12/2015
1	Aftercare (After-Treatment) 06/2004
1	Intravenous Administration 01/2002